These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Recent advances in understanding the pathogenesis of Huntington's disease. Reddy PH; Williams M; Tagle DA Trends Neurosci; 1999 Jun; 22(6):248-55. PubMed ID: 10354600 [TBL] [Abstract][Full Text] [Related]
4. The paradigm of Huntington's disease: therapeutic opportunities in neurodegeneration. Leegwater-Kim J; Cha JH NeuroRx; 2004 Jan; 1(1):128-38. PubMed ID: 15717013 [TBL] [Abstract][Full Text] [Related]
5. Similar Progression of Morphological and Metabolic Phenotype in R6/2 Mice with Different CAG Repeats Revealed by In Vivo Magnetic Resonance Imaging and Spectroscopy. Sawiak SJ; Wood NI; Morton AJ J Huntingtons Dis; 2016 Oct; 5(3):271-283. PubMed ID: 27662335 [TBL] [Abstract][Full Text] [Related]
6. Etiology of (CAG)n triplet repeat neurodegenerative diseases such as Huntington's disease is connected to stimulation of glutamate receptors. Fischer KM Med Hypotheses; 1997 May; 48(5):393-8. PubMed ID: 9185124 [TBL] [Abstract][Full Text] [Related]
7. Increased calbindin-D28k immunoreactivity in striatal projection neurons of R6/2 Huntington's disease transgenic mice. Sun Z; Wang HB; Deng YP; Lei WL; Xie JP; Meade CA; Del Mar N; Goldowitz D; Reiner A Neurobiol Dis; 2005 Dec; 20(3):907-17. PubMed ID: 15990326 [TBL] [Abstract][Full Text] [Related]
9. Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice. Morton AJ; Glynn D; Leavens W; Zheng Z; Faull RL; Skepper JN; Wight JM Neurobiol Dis; 2009 Mar; 33(3):331-41. PubMed ID: 19130884 [TBL] [Abstract][Full Text] [Related]
10. Mind the gap: models in multiple species needed for therapeutic development in Huntington's disease. Howland DS; Munoz-Sanjuan I Mov Disord; 2014 Sep; 29(11):1397-403. PubMed ID: 25155258 [TBL] [Abstract][Full Text] [Related]
11. Animal models of Huntington's disease: implications in uncovering pathogenic mechanisms and developing therapies. Wang LH; Qin ZH Acta Pharmacol Sin; 2006 Oct; 27(10):1287-302. PubMed ID: 17007735 [TBL] [Abstract][Full Text] [Related]
12. Weight loss in Huntington disease increases with higher CAG repeat number. Aziz NA; van der Burg JM; Landwehrmeyer GB; Brundin P; Stijnen T; ; Roos RA Neurology; 2008 Nov; 71(19):1506-13. PubMed ID: 18981372 [TBL] [Abstract][Full Text] [Related]
14. Novel BAC Mouse Model of Huntington's Disease with 225 CAG Repeats Exhibits an Early Widespread and Stable Degenerative Phenotype. Wegrzynowicz M; Bichell TJ; Soares BD; Loth MK; McGlothan JS; Mori S; Alikhan FS; Hua K; Coughlin JM; Holt HK; Jetter CS; Pomper MG; Osmand AP; Guilarte TR; Bowman AB J Huntingtons Dis; 2015; 4(1):17-36. PubMed ID: 26333255 [TBL] [Abstract][Full Text] [Related]
15. Of molecular interactions, mice and mechanisms: new insights into Huntington's disease. Wellington CL; Hayden MR Curr Opin Neurol; 1997 Aug; 10(4):291-8. PubMed ID: 9266152 [TBL] [Abstract][Full Text] [Related]
16. Normal sensitivity to excitotoxicity in a transgenic Huntington's disease rat. Winkler C; Gil JM; Araújo IM; Riess O; Skripuletz T; von Hörsten S; Petersén A Brain Res Bull; 2006 Apr; 69(3):306-10. PubMed ID: 16564426 [TBL] [Abstract][Full Text] [Related]
17. Epigenetic mechanisms of neurodegeneration in Huntington's disease. Lee J; Hwang YJ; Kim KY; Kowall NW; Ryu H Neurotherapeutics; 2013 Oct; 10(4):664-76. PubMed ID: 24006238 [TBL] [Abstract][Full Text] [Related]